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Abstract
Diagnostics spanning a wide range of new biotechnologies, including proteomics, metabolomics, and nano-
technology, are emerging as companion tests to innovative medicines. In this Opinion, we present the rationale
for promulgating an ‘‘Essential Diagnostics List.’’ Additionally, we explain the ways in which adopting a vision
for ‘‘Health in All Policies’’ could link essential diagnostics with robust and timely societal outcomes such as
sustainable development, human rights, gender parity, and alleviation of poverty. We do so in three ways. First,
we propose the need for a new, ‘‘see through’’ taxonomy for knowledge-based innovation as we transition from
the material industries (e.g., textiles, plastic, cement, glass) dominant in the 20th century to the anticipated
knowledge industry of the 21st century. If knowledge is the currency of the present century, then it is sensible to
adopt an approach that thoroughly examines scientific knowledge, starting with the production aims, methods,
quality, distribution, access, and the ends it purports to serve. Second, we explain that this knowledge trajectory
focus on innovation is crucial and applicable across all sectors, including public, private, or public–private
partnerships, as it underscores the fact that scientific knowledge is a co-product of technology, human values,
and social systems. By making the value systems embedded in scientific design and knowledge co-production
transparent, we all stand to benefit from sustainable and transparent science. Third, we appeal to the global
health community to consider the necessary qualities of good governance for 21st century organizations that
will embark on developing essential diagnostics. These have importance not only for science and knowledge-
based innovation, but also for the ways in which we can build open, healthy, and peaceful civil societies today
and for future generations.
‘‘[R]evolutionary situations arise also in science when the legitimacy of the previously accepted order and ways
of ‘doing things’ are questioned and eventually overthrown.’’
Helga Nowotny (2007)
The Concept of Essential Medicines
The global health community recognizes thevalue and importance of ensuring populations have
adequate and reliable access to certain medicines. Health
authorities in countries need to know what to prioritize to
ensure they have a basic health care system that can ade-
quately serve the needs of the population. In this regard, the
history of essential medicines is relatively recent. Consider
that aspirin was only introduced in 1897 as the first synthetic
pharmaceutical, and is arguably the first truly essential
medicine that aimed to satisfy the health care needs of the
majority of the population. Although the history is recent,
already the concept of essential medicines is well recognized.
In 1977, theWorld Health Organization (WHO) launched the
forward-looking and dynamic ‘‘Model List of Essential
Medicines’’, and identified 208 individual medicines which
together could provide safe, effective treatment for the ma-
jority of communicable and non-communicable diseases.
The List is updated every 2 years by an international expert
committee.
Essential medicines are ‘‘those that satisfy the priority health
care needs of the population,’’ selected based on disease burden,
efficacy, safety, and cost-effectiveness evidence (World Health
Organization, 2013). The medicines listed are ‘‘intended to be
available within the context of functioning health systems at all
times in adequate amounts, in the appropriate dosage forms,
with assured quality, and at a price the individual and the
community can afford’’ (World Health Organization, 2013).
The List is not intended as a global standard. Each country, or
states within countries,may adopt the list of essentialmedicines
based on local context and priorities.
Pharmaceuticals represent up to 66% of health-related
expenditures in developing countries (World Health Orga-
nization, 2013). Since many international and nongovern-
mental organizations (NGOs) consider it as a guidepost, the
List also assists in procurement, reimbursement, access,
quality, and rational use of medicines. Essential medicines
are often associated with principles of equity, pro-poor pol-
icies, and good governance. The latest 19th WHOModel List
of Essential Medicines was published in May 2015 (World
Health Organization, 2015). As important as an essential
medicines list is for all countries, science and medicine have
moved into new areas, accelerated in no small measure by
Big Data (Sxardasx et al. 2014). This shift in science and
medicine, and health care delivery, calls for innovative
thinking to develop new governance tools that address the
pressing health care needs of populations.
What about Essential Diagnostics?
Social studies of science scholar Helga Nowotny has
noted that radically new ways of ‘‘doing things’’ emerge in
the course of scientific practices (Nowotny, 2007). A
crosscutting change, precision medicine develops and
makes use of diagnostic tests that, through stratification,
explain the basis of large person-to-person (or subgroup)
variations in drug safety and efficacy. Beyond targeting
medicines to the right person at the right dose, precision
medicine also signals a shift from treatment to preven-
tion in healthcare, ranging from identification of those at
highest risk of developing a disease, adverse drug reactions
(ADRs), treatment failures, to those who would benefit
most from preventive interventions.
The benefit of precision medicine to countries can be
profound, not just in terms of promoting healthy aging, but
also in realization of socioeconomic benefits. Using a health
simulation model, a recent analysis published in The Lancet
suggests that the years of healthy life that can be cultivated
by a precision medicine approach in six diseases (cancer,
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diabetes, heart disease, high blood pressure, lung disease, and
stroke) in the US population could generate, in the case of
heart diseases, an impressive $607 billion in improved health
over the next 50 years (Dzau et al., 2015).
Diagnostics spanning a wide range of biotechnologies,
including genomics, proteomics, metabolomics, and nano-
technology, are emerging as companion tests to innova-
tive medicines (Conde and Artzi, 2015; Higdon et al., 2015).
The 19th WHO Model List of Essential Medicines brings
to the fore innovative medicines for hepatitis C, breast can-
cer, leukemia, and multi-drug resistant tuberculosis (World
Health Organization, 2015). Innovative medicines desig-
nated as ‘‘essential’’ can have enormous positive impacts
on global health. Furthermore, innovative medicines might
have even broader reception in future Essential Medicines
Lists if we consider therapeutics with companion ‘‘essential
diagnostics’’ aimed at prevention of ADRs and ineffective
treatments.
Too often, however, diagnostics are overlooked as a crit-
ical component of modern health care (ElRakaiby et al.,
2014; O¨zdemir and Cho, 2012). From a discovery science
standpoint, not all innovative medicines may attain the status
of an ‘‘essential medicine.’’ But they are more likely to
emerge out of the laboratory and ‘‘into the street’’ if we move
away from the traditional one-size-fits-all model of drug
development by recognizing the multi-omics basis of person-
to-person heterogeneity in drug safety and efficacy by diag-
nostic tests (Higdon et al. 2015; O¨zdemir and Lerer, 2005).
When an innovative medicine attached to a companion di-
agnostic is granted an essential medicine status, there is a
need for parallel policy and regulatory mechanisms to govern
and evaluate the diagnostic counterpart of such innovative
essential medicines.
Thus, we propose and call for the development of an Es-
sential Diagnostics List, which is comprised of the necessary
diagnostics for robust and crosscutting impacts on global
health, as well as societal endpoints such as sustainable de-
velopment, gender parity, global health diplomacy/security,
and inclusive and peaceful societies, among others. These
essential diagnostics should bemade available in an evidence-
based, cost effective, and ethical manner at all times in health
systems, together with essential medicines. An Essential
Diagnostics List in an era of precision (stratified) medi-
cine offers a real opportunity to improve rational therapy
and health outcomes in subpopulations defined by diag-
nostic tests (Fig. 1) (O¨zdemir and Lerer, 2005; Tutton,
2012). Essential diagnostics and essential medicines are
two sides of the same coin for rational therapeutics, and
complement each other as concepts and practices (Fig. 2).
An Essential Diagnostics List places global health firmly
on the life sciences innovation agenda. At the same time, we
neither neglect nor underestimate potential trepidation that
might exist within the global health community towards de-
veloping a list of essential diagnostics. Public health had a
longstanding and laudable focus on addressing the needs of
the entire population, but this view also risks treating com-
munities as homogeneous organisms, overlooking the diverse
needs of distinct subpopulations defined both by variations in
biology and environment.
In the future, by using an essential diagnostic test, an in-
novative essential medicine might target a subpopulation
wherein it may display maximum efficacy and minimum
toxicity. No doubt this will (and ought to) raise ethical con-
cerns about what may come of other subpopulations with
unmet therapeutic needs. But one should also consider that
failure to prevent ADRs and ineffective treatments, while
diagnostics are increasingly available to identify at risk
populations, is an ethical concern in its own right.
In this era of Big Data analytics and precision medicine,
we must face proactively the reality that many biomarker
FIG. 1. Precision medicine visualized as stratified medicine and enabling rational
therapeutics in subpopulations defined by global health relevant essential diagnostics.
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claims and diagnostics candidates are in transition from lab to
applications as precision medicine diagnostics worldwide
(Sxardasx et al., 2014). This has already created unmet policy
gaps on diagnostics in regards to what needs to be considered
as ‘‘essential’’ for global health versus clinical practice ver-
sus personal utility versus recreational diagnostic tests with
dubious value. Moreover, the impacts of new diagnostics on
global health and societal endpoints regrettably are not often
considered as a major criterion for adoption. We think such a
criterion would be essential beyond clinical and personal
utility for a diagnostic to be deemed ‘‘essential’’ (Fig. 2). An
Essential Diagnostics List would help preserve scientific
rigor and standards in resource-limited settings laden with
economic, social, geographical and political instability or
pseudo-scientific actors (Dandara et al., 2014; O¨zdemir,
2014; O¨zdemir et al., 2013; 2015a).
Having an Essential Diagnostics List in place could also
serve as a guidepost to prevent ‘‘parachute science’’ in re-
source-limited regions that exploit local communities, their
populations, and biodiversity, as de Vries and Pepper note:
The trend has been to use data derived from African popu-
lations to build research programmes and enhance individual
careers in more affluent communities with little or no con-
sideration for the populations from which this material was
derived. (de Vries and Pepper, 2012).
At the same time, we must not leap into assumptions about
where precision medicine is most achievable or suitable. In
the 21st century, old binaries such as developed and devel-
oping country are increasingly blurred (Dove, 2013; Haffeld
and Siem, 2013; O¨zdemir, 2015a). Peter Hotez has aptly
noted that resource-constrained regions exist not only in
developing world but also in major geographical parts of the
G20 nations and the developed countries (Hotez, 2013). An
Essential Diagnostics List would serve the global health
community well as a new technology and innovation gov-
ernance instrument.
Linking Diagnostics to Broad Societal Impacts
Health in All Policies (HiAP)
A key criterion for an essential diagnostic is veritable
linkages with and impacts on broad societal outcomes beyond
clinical utility (Fig. 2). A corollary of this is that the value of
essential diagnostics cannot be deciphered solely through
looking from inside the health ecosystem and related orga-
nizational structures. We need to look at health from the
outside as well. Understanding health innovations such as
essential diagnostics across sectors demands shared gover-
nance and knowledge of the ‘‘languages’’ and ‘‘ways of
knowing’’ by other disciplines—in particular, anthropology,
sociology, philosophy, and political science.
In the same way that molecular biology has made visible
the pathways underlying diseases normally invisible to the
naked eye—social science and humanities scholarship equips
us with the knowledge of invisible societal and micro-level
contexts and dynamics that shape, and are shaped by, sci-
entific practices. In short, such interdisciplinary scholarship
is instrumental to understanding the inner workings of human
societies and the socio-material environments in which they
are entrenched. For example, without a social sciences and
humanities lens, we run the risk of turning a blind eye,
willfully or unintentionally, to important justice issues such
as human rights, ethics, and power dynamics in scientific
practice, gender gaps, rural versus urban communities’
FIG. 2. Linking the selection of essential diagnostics to broad societal outcomes and
crosscutting governance instruments such as ‘‘Health in All Policies’’ (HiAP) and ‘‘See-
Through Science and Ethics.’’
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access to health in global society, and the structural and
psychosocial constraints of laboratory and professional life.
If we are to link the selection of essential diagnostics not
only to clinical utility but also to societal impacts, we
need additional governance instruments grounded in social
science and humanities, as well as (natural) science and
technology. Health in All Policies (HiAP) is one such
governance instrument that we suggest should be consid-
ered in tandem with decisions concerning the proposed
Essential Diagnostics Lists. HiAP values the systems
approaches often discussed in OMICS: A Journal of In-
tegrative Biology; it highlights the need to heed both
‘‘trees’’ and ‘‘forests’’ to address complex life sciences and
related societal challenges and opportunities.
HiAP examines, analyzes, and engages with health and
non-health sectors to understand the root causes of illness and
good health. In the context of HiAP, Ilona Kickbusch has
noted the value of bi-directional linkages between health and
sectors that are traditionally considered as being outside the
scope of health and life sciences. These can include sectors
such as global health diplomacy, security, and development:
This is critical for twenty-first century health policy because
good or bad health outcomes depend on the action of other
sectors but also affect the outcomes of a wide range of other
sectors. (Kickbusch, 2010).
Gender parity and maternal health diagnostics
Essential diagnostics, if evaluated under the overarching
frame of HiAP, could offer firm linkages with societal and
global health endpoints neglected previously, such as gender
parity. The World Economic Forum, amongst others, has
asserted that gender parity is an indispensible dimension of
21st century organizations and society (World Economic
Forum, 2015). Novel diagnostics impacting maternal health
and by extension, gender parity, are important on principled
ethics and human rights grounds as well (Tasioulas and
Vayena, 2015).
A pharmacogenomics peace and conflict
resolution clinic
Yet another novel example of potential broader societal
impacts of essential diagnostics could be drawn from the field
of pharmacogenomics. Cytochrome P450 2D6 (CYP2D6) is
one of the most intensively studied drug metabolizing en-
zymes, with extensive polymorphic pharmacogenomics var-
iation across world populations. Aklillu and colleagues have
shown that in Ethiopia, 29% of the study sample carried al-
leles with duplicated or multiduplicated CYP2D6 genes, in-
dicative of ultra-rapid metabolism, and which often leads
to treatment failure (Aklillu et al., 1996). Owing in part to
historical human migration patterns, there is a gradient (from
high to low) of CYP2D6 ultra-rapid metabolizers from
Ethiopia to the Middle East to Spain and Northern Europe
(O¨zdemir et al., 2006). Because conflict and war are not un-
common in certain points on this historical migration route
(e.g., consider the ongoing conflict in Syria and the Middle
East), conflicted populations that share similar genetic make-
up, and thus need shared solutions for diagnostic tests for
rational therapy, might be able to reconcile their perceived
differences or at least ‘‘agree to disagree’’ in a peaceful
manner when global health services are provided for shared
health needs.
Moreover, a global health diplomacy and security initia-
tive of CYP2D6 testing and other diagnostics could offer a
health-based conflict resolution forum. This would resonate
very well with the ethos of HiAP.While we do not have HiAP
in place in most parts of the world, these examples might help
commence a multi-sector discourse on the subject matter of
essential diagnostics in regions and for global health appli-
cations where HiAP is most needed.
Finally, as a complement to traditional academic pub-
lishing with a generally modest global circulation, engaging
with mass media, both traditional and social, and in multiple
languages, might offer ways forward for broader engage-
ments central to HiAP. We suggest a need for greater en-
gagement between scientists, communication sciences and
mass media in ways that are credible, trustworthy, held ac-
countable to and driven by society (Zhao et al., 2014).
Who Shall Take on the Task? Designing
New 21st Century Organizations
Governing innovations by ‘‘see-through science
and ethics’’
From the invention of steam power at the beginning of
the Industrial Revolution, to the growth of material indus-
tries (e.g., textiles, glass, cement, plastics) over the last 2
centuries, there has been a longstanding tradition to classify
organizations as public, private, and public–private partner-
ship, among others. As we transition to a new revolution
based not on manufacturing so much as ‘‘mensafacturing’’
(intellectual outputs), centered on knowledge society and
much-hoped for knowledge-based innovations such as global
health diagnostics (Dove, 2013; O¨zdemir, 2014), we need a
new taxonomy of workplace and organizations. If knowledge
is the currency of the current century, then we must think
anew about organizational taxonomy informed by an ap-
proach that examines knowledge from all points, from its
production aims, means, quality, distribution, access, and to
the ends it serves (Birko et al., 2015; Dove and O¨zdemir,
2013; European Commission, 2007; Yearley, 2004).
Hence, this Opinion does not aim to appeal to any one
particular organization, public, private, nongovernmental,
nor any conceivable international agency, to take on the task
of developing and promoting an Essential Diagnostics List.
Instead, it aims to appeal to the readers of this journal and
global health community at large, to consider thinking about
the necessary qualities of new 21st century organizations
before a discussion is launched to determine which actors
should take on this challenging task.
No doubt, we need innovation in institutional design as
well. Twenty-first century universities are sorely in need of
evolution towards an expanded and productive dialogue be-
tween science and society (Callon et al. 2011; Nowotny,
2007). It is uncertain whether the current university designs
and research funding mechanisms as we know them can
adequately meet the challenges and prospects of emerging
technologies and novel diagnostics (O¨zdemir et al., 2015b).
Rather than convergent thinking, this is a time for divergent
thinkers and perhaps unorthodox or ‘‘indie’’ and off-road
organizations to come up with innovative institutional rede-
signs of 21st century science.
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A starting point is to re-think scientific organizations (be-
yond research universities and the binaries of public versus
private) and unpack the ways in which knowledge is co-pro-
duced together with values introduced by a range of actors, be
they publics, scientists, citizen scientists, funders, academics,
industry, governments, or policymakers. This ‘‘trajectory’’ fo-
cus is crucial and applicable across all sectors because it un-
derscores the fact that scientific knowledge is a co-product of
technology, human values, and social systems. By making the
value systems embedded in scientific knowledge production
transparent, we all stand to benefit from sustainable and
transparent science (Birch and Tyfield, 2013; O¨zdemir, 2015).
Thinking about the ways in which science is constructed
is not an intellectual project that ended with the Enlight-
enment. We continue to make the case, conceptually and
empirically, that knowledge experts bring their socially
constructed values to the laboratory and influence, and are
influenced by, the social and political systems that charac-
terize their fields. Although the long-held, widely accepted
version of scientific history since the early luminaries of the
Enlightenment has promoted the view that scientific prac-
tice and knowledge are neutral, value free, and inherently
objective, we know this is more myth than reality (Birko
et al., 2015; Callon et al., 2011; Dove and O¨zdemir, 2013;
Editorial, 2013; Yearley, 2004). For example, while scien-
tific evidence is considered an important gatekeeper for
adoption of diagnostics, it also begs the question of ‘‘which
evidence’’ produced ‘‘by whom’’, to benefit ‘‘which
stakeholders,’’ and under ‘‘what societal context, values and
priorities’’ (Birko et al., 2015; Nowotny, 2007).
To enable a broad and open discussion of essential diag-
nostics, therefore, we offer below a taxonomy, in part
building on nested governance systems designed by the late
Elinor Ostrom (Ostrom, 1990), and in part based on our past
synthesis for omics systems sciences (Dove et al., 2012;
O¨zdemir et al., 2015a). Here, knowledge experts are classi-
fied as actors (e.g., scientists producing knowledge), narra-
tors (e.g., ethicists, social scientists and humanists observing
and analyzing knowledge co-production practices), and in-
dependent blue skies scholars (IBSS) who generate and an-
alyze ‘‘social metadata’’ on the sorts of questions noted
above that impact not only scientists, but also ethicists’ and
social scientists’ daily practices (Dove et al., 2012; Dove and
O¨zdemir, 2014; O¨zdemir et al., 2015a) (Fig. 3).
Such a taxonomy of the innovation trajectory makes ex-
plicit that no knowledge expert is ‘‘above the fray’’: all shall
remain accountable and make their practices transparent. The
taxonomy invites us to be self-critical and reflexive (e.g., how
do our own values, motivations, and expectations influence
our actions and the conclusions we reach?). Through the tri-
adic taxonomy described in Figure 3, knowledge experts can
create a trustworthy and ‘‘see-through science and ethics’’
FIG. 3. A triadic taxonomy and design for ‘‘See-Through Science and Ethics’’ and new
21st century scientific institutions for knowledge-based innovations. These envisioned 21st
century organizational re-designs of work and society could contribute to the proposed
post-2015 United Nations Sustainable Development Goals (SDGs) such as peaceful and
inclusive societies. At the heart of the proposed taxonomy rests ‘‘nested architectures’’ that
help foster environments of transparency and trustworthiness, and balanced power in
society and its science and technology institutions. The proposed taxonomy is comprised
of Actors who produce knowledge (e.g., scientists), Narrators (e.g., social scientists,
humanists, ethicists) who observe the actors and their practices in real-time, and
Independent Blue Skies Scholars (IBSS) who are not entrenched in traditional profes-
sional network structures (e.g., independent scholars, scholars-in-residence, society-driven
self-organized groups or citizen scientists), and thus can offer truly independent broad
systems-oriented (blue skies) analyses of both actors’ and narrators’ practices. The term
IBSS was coined in an earlier article (O¨zdemir et al., 2015a).
6 DOVE ET AL.
knowledge commons where power differences among the
ecosystem’s actors and narrators are kept in check in real-
time. This proposed model warrants field-testing and should
be compared to existing science organizations in regards to
impacts on sustainable science and responsible innovation.
Conclusions
With the arrival of Big Data and many biomarker claims—
some valid and others less valid or even irrelevant—developing
essential diagnostics will be critical if we are to link technology
to responsible innovation in ways that concretely and positively
impact global health. Developing an Essential Diagnostics List
provides an opportunity to harness the latest science and di-
agnostic technology to establish linkages with health policies
that are crosscutting across sectors inside and outside health
(e.g., the application of whole genome sequencing in pharma-
cogenomics) (Mizzi et al., 2014), and with science and ethics
that are fully transparent and held accountable to global society.
This we hold to be essential, too, not only for global health and
knowledge-based innovation, but also for the ways inwhich we
can build open, healthy, and peaceful civil societies today and
for future generations.
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